AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?

Company Performance - AxoGen (AXGN) shares have increased by 8.8% over the past month and reached a new 52-week high of $10.65, with a year-to-date gain of 51.8% compared to 7.9% for the Zacks Medical sector and 6.3% for the Zacks Medical - Instruments industry [1] - The company has consistently exceeded earnings expectations, reporting EPS of $0.01 against a consensus estimate of $-0.08 in its last earnings report on November 7, 2023 [2] Financial Projections - For the current fiscal year, AxoGen is projected to earn $0.03 per share on revenues of $158.8 million, with a year-over-year earnings growth of 118.75% [2] - For the next fiscal year, earnings are expected to rise to $0.17 per share on revenues of $178.5 million, representing a year-over-year change of 12.41% [2] Valuation Metrics - AxoGen's current trading valuation is at 345.7X current fiscal year EPS estimates, significantly higher than the peer industry average of 27.9X [4] - On a trailing cash flow basis, the stock trades at 5X compared to the peer group's average of 13.1X, indicating a less favorable value perspective [4] Zacks Rank and Style Scores - AxoGen holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, suggesting potential for future growth [5] - The company has a Value Score of C, a Growth Score of B, and a Momentum Score of C, resulting in a combined VGM Score of B [3] Industry Comparison - Artivion, Inc. (AORT), a peer in the industry, has a Zacks Rank of 1 (Strong Buy) and has shown strong earnings performance, beating consensus estimates by 184.62% [6] - The Medical - Instruments industry is positioned in the top 38% of all industries, indicating favorable conditions for both AxoGen and Artivion [6]